A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
A Single-Center, Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
Sponsor: Hoffmann-La Roche
Listed as NCT03380780, this PHASE1 trial focuses on Healthy Volunteers and Hemophilia A and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 8 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — Oct 2019 [monthly]
Completed PHASE1
-
Dec 2018 — Aug 2019 [monthly]
Completed PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Apr 2018 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .